TWI316511B - Calcilytic compounds - Google Patents
Calcilytic compounds Download PDFInfo
- Publication number
- TWI316511B TWI316511B TW092132853A TW92132853A TWI316511B TW I316511 B TWI316511 B TW I316511B TW 092132853 A TW092132853 A TW 092132853A TW 92132853 A TW92132853 A TW 92132853A TW I316511 B TWI316511 B TW I316511B
- Authority
- TW
- Taiwan
- Prior art keywords
- propoxy
- phenyl
- ethylamino
- propionic acid
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
- C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
- C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42910502P | 2002-11-26 | 2002-11-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200510276A TW200510276A (en) | 2005-03-16 |
| TWI316511B true TWI316511B (en) | 2009-11-01 |
Family
ID=32393505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW092132853A TWI316511B (en) | 2002-11-26 | 2003-11-24 | Calcilytic compounds |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US7514473B2 (es) |
| EP (1) | EP1569892B1 (es) |
| JP (1) | JP4489597B2 (es) |
| KR (2) | KR20050086786A (es) |
| CN (1) | CN1325466C (es) |
| AP (1) | AP2113A (es) |
| AR (1) | AR042132A1 (es) |
| AU (1) | AU2003291157C1 (es) |
| BR (1) | BR0316544A (es) |
| CA (1) | CA2507226C (es) |
| CO (1) | CO5570664A2 (es) |
| CY (1) | CY1113083T1 (es) |
| DK (1) | DK1569892T3 (es) |
| EA (1) | EA009603B1 (es) |
| ES (1) | ES2388277T3 (es) |
| IL (1) | IL168704A (es) |
| IS (1) | IS2897B (es) |
| MA (1) | MA27528A1 (es) |
| MX (1) | MXPA05005574A (es) |
| MY (1) | MY143244A (es) |
| NO (1) | NO332304B1 (es) |
| NZ (1) | NZ540275A (es) |
| OA (1) | OA12962A (es) |
| PE (1) | PE20040845A1 (es) |
| PL (1) | PL211571B1 (es) |
| PT (1) | PT1569892E (es) |
| SI (1) | SI1569892T1 (es) |
| TW (1) | TWI316511B (es) |
| UA (1) | UA81642C2 (es) |
| UY (1) | UY28089A1 (es) |
| WO (1) | WO2004047751A2 (es) |
| ZA (1) | ZA200504104B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY143244A (en) * | 2002-11-26 | 2011-04-15 | Smithkline Beecham Corp | Calcilytic compounds |
| US7318925B2 (en) | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
| JP2007521232A (ja) | 2003-08-08 | 2007-08-02 | アブジェニックス・インコーポレーテッド | 副甲状腺ホルモン(pth)に対する抗体およびその使用 |
| WO2005077886A1 (en) * | 2004-02-06 | 2005-08-25 | Smithkline Beecham Corporation | Calcilytic compounds |
| TW200845956A (en) * | 2006-12-18 | 2008-12-01 | Smithkline Beecham Corp | Calcilytic compounds |
| PT2292592E (pt) | 2008-06-05 | 2012-11-12 | Asahi Kasei Pharma Corp | Composto de sulfonamida e sua aplicação |
| BRPI0922503A2 (pt) | 2008-12-24 | 2018-11-06 | Daiichi Sankyo Company, Limited | composto, composição farmacêutica, métodos para melhorar o metabolismo ósseo, e para previnir ou tratar osteoporose |
| GB201217330D0 (en) | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
| WO2015196205A1 (en) * | 2014-06-20 | 2015-12-23 | Glaxosmithkline Llc | Method of using calcilytic compounds to treat diseases of abnormal glucose or insulin levels |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE298506C (es) | ||||
| US643656A (en) * | 1898-09-03 | 1900-02-20 | Francis Keil | Mold for lock-cylinders and key-hubs. |
| ES421076A1 (es) | 1973-12-01 | 1976-04-01 | Andreu Sa Dr | Procedimiento para la obtencion de 1-ariloxi-3-aralquilami-no-2-propanoles. |
| ES442062A1 (es) | 1975-10-24 | 1977-04-01 | Andreu Sa Dr | Procedimiento para la obtencion de 1-ariloxi-2-hidroxi-3- alquilaminopropanos. |
| DE2644833A1 (de) * | 1976-10-05 | 1978-04-20 | Boehringer Sohn Ingelheim | Neue 1-aryloxy-2-hydroxy-3-alkylenaminopropane und verfahren zu ihrer herstellung |
| CH618335A5 (es) * | 1977-05-31 | 1980-07-31 | Arnegger Richard E | |
| US4234595A (en) * | 1977-07-13 | 1980-11-18 | Mead Johnson & Company | 3-Indolyl-tertiary butylaminopropanols |
| IT1101724B (it) * | 1978-12-05 | 1985-10-07 | Erba Carlo Spa | Derivati morfolinici e fenossiprofanolaminici e procedimento per la loro preparazione |
| IL56369A (en) * | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
| GB2014968A (en) | 1978-02-24 | 1979-09-05 | Pearson J | Article handling apparatus |
| US4495352A (en) * | 1979-02-13 | 1985-01-22 | Mead Johnson & Company | Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols |
| ES480066A1 (es) | 1979-04-28 | 1980-04-01 | Especialid Latin Medicam Unive | Procedimiento de obtencion de 1-4-cloro-&,&-dimetil-benceno-etanamino-2-oxi-3 ariloxi propanos. |
| DE3544172A1 (de) * | 1985-12-13 | 1987-06-19 | Lentia Gmbh | Neue kristalline salze von aryloxy-propanolaminen, verfahren zu ihrer herstellung und ihre verwendung |
| FR2601008B1 (fr) * | 1986-07-03 | 1990-03-30 | Sanofi Sa | Procede de synthese stereospecifique de derives de l'indole |
| DD298506A5 (de) * | 1988-12-30 | 1992-02-27 | Ernst-Moritz-Arndt-Universitaet Greifswald,De | Verfahren zur herstellung halogensubstituierter 1-phenoxy-3-alkylamino-propan-2-ole |
| DE4040186A1 (de) | 1989-12-20 | 1991-06-27 | Hoechst Ag | Hypoglykaemisch aktive propandiolaminderivate mit insulin-aehnlicher wirkung und deren verwendung, neue propandiolaminderivate, diese substanzen enthaltende pharmazeutische zubereitungen und ihre verwendung zur behandlung von krankheiten |
| HN1996000101A (es) | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| WO1997037967A1 (en) | 1996-04-09 | 1997-10-16 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
| US6818660B2 (en) * | 1996-04-09 | 2004-11-16 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
| US20020019440A1 (en) * | 1996-11-05 | 2002-02-14 | Virbac Sa | Aryloxypropanolamine derivatives, method of preparation and applications thereof |
| US7202261B2 (en) * | 1996-12-03 | 2007-04-10 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
| TW483881B (en) * | 1996-12-03 | 2002-04-21 | Nps Pharma Inc | Calcilytic compounds |
| CA2285556A1 (en) | 1997-04-04 | 1998-10-15 | Smithkline Beecham Corporation | Calcilytic compounds |
| UY24949A1 (es) * | 1997-04-08 | 2001-04-30 | Smithkline Beecham Corp | Compuestos calcilíticos |
| DE19913753A1 (de) | 1998-04-01 | 1999-10-07 | Mannesmann Rexroth Ag | Verfahren zur Bildung des Mittelwertes |
| MY121054A (en) | 1998-04-08 | 2005-12-30 | Smithkline Beecham Corp | Calcilytic compounds as calcium receptor antagonists. |
| AR014975A1 (es) | 1998-04-08 | 2001-04-11 | Nps Pharma Inc | Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento |
| WO2000009132A1 (en) * | 1998-08-12 | 2000-02-24 | Smithkline Beecham Corporation | Calcilytic compounds |
| JP2002522532A (ja) * | 1998-08-12 | 2002-07-23 | スミスクライン・ビーチャム・コーポレイション | カルシウム分解化合物 |
| PE20001456A1 (es) * | 1999-02-02 | 2001-01-28 | Smithkline Beecham Corp | Compuestos calcioliticos |
| WO2001007026A2 (en) | 1999-07-22 | 2001-02-01 | Eli Lilly And Company | Improved method of treating type ii diabetes and obesity |
| CO5180628A1 (es) | 1999-07-31 | 2002-07-30 | Smithkline Beecham Corp | Compuestos calcioliticos |
| MY159417A (en) * | 2000-01-24 | 2017-01-13 | Smithkline Beecham Corp | Calcilytic compounds |
| US20030018203A1 (en) * | 2002-07-17 | 2003-01-23 | Largo Maria Amparo | Calcilytic compounds |
| KR20030017642A (ko) | 2000-07-21 | 2003-03-03 | 스미스클라인 비참 코포레이션 | 칼실리틱 화합물 |
| EP1383511B1 (en) | 2000-10-25 | 2006-10-25 | SmithKline Beecham Corporation | Calcilytic compounds |
| PL365643A1 (en) | 2000-10-25 | 2005-01-10 | Smithkline Beecham Corporation | Calcilytic compounds |
| WO2002072760A2 (en) | 2001-03-08 | 2002-09-19 | Smithkline Beecham Corporation | Pcra helicase inhibitors |
| US6864267B2 (en) * | 2001-07-16 | 2005-03-08 | Smithkline Beecham Corporation | Calcilytic compounds |
| MY143244A (en) | 2002-11-26 | 2011-04-15 | Smithkline Beecham Corp | Calcilytic compounds |
| EP1613606A4 (en) * | 2003-04-07 | 2008-12-03 | Nps Pharma Inc | PROCESS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES |
| AU2004266705A1 (en) * | 2003-08-20 | 2005-03-03 | Nitromed, Inc. | Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use |
| AR045799A1 (es) * | 2003-09-24 | 2005-11-16 | Glaxo Group Ltd | Compuesto 6- oxo-2,5- dioxabiciclico y su uso para preparar una composicion farmaceutica |
| WO2005030746A1 (en) | 2003-09-24 | 2005-04-07 | Glaxo Group Limited | Calcilytic compounds |
| WO2005077892A1 (en) | 2004-02-06 | 2005-08-25 | Smithkline Beecham Corporation | Calcilytic compounds |
| NL1025457C1 (nl) | 2004-02-11 | 2005-08-12 | Rudolf Johannes Gerardus Hoorn | Haspelrem. |
| AU2005304770A1 (en) | 2004-11-08 | 2006-05-18 | Nicox S.A. | Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders |
| JP2008528507A (ja) | 2005-01-21 | 2008-07-31 | ニトロメッド インコーポレーティッド | 複素環式の酸化窒素供与体基を含む心血管化合物、組成物および使用方法 |
-
2003
- 2003-11-24 MY MYPI20034511A patent/MY143244A/en unknown
- 2003-11-24 TW TW092132853A patent/TWI316511B/zh not_active IP Right Cessation
- 2003-11-24 UY UY28089A patent/UY28089A1/es unknown
- 2003-11-24 AR ARP030104333A patent/AR042132A1/es not_active Application Discontinuation
- 2003-11-25 CA CA2507226A patent/CA2507226C/en not_active Expired - Fee Related
- 2003-11-25 NZ NZ540275A patent/NZ540275A/en not_active IP Right Cessation
- 2003-11-25 WO PCT/US2003/037461 patent/WO2004047751A2/en not_active Ceased
- 2003-11-25 KR KR1020057009379A patent/KR20050086786A/ko not_active Ceased
- 2003-11-25 KR KR1020117025893A patent/KR101142697B1/ko not_active Expired - Fee Related
- 2003-11-25 UA UAA200505005A patent/UA81642C2/ru unknown
- 2003-11-25 US US10/536,416 patent/US7514473B2/en not_active Expired - Fee Related
- 2003-11-25 PE PE2003001196A patent/PE20040845A1/es not_active Application Discontinuation
- 2003-11-25 BR BR0316544-2A patent/BR0316544A/pt active Search and Examination
- 2003-11-25 PL PL376965A patent/PL211571B1/pl unknown
- 2003-11-25 JP JP2004555635A patent/JP4489597B2/ja not_active Expired - Fee Related
- 2003-11-25 EA EA200500878A patent/EA009603B1/ru not_active IP Right Cessation
- 2003-11-25 SI SI200332179T patent/SI1569892T1/sl unknown
- 2003-11-25 ES ES03783752T patent/ES2388277T3/es not_active Expired - Lifetime
- 2003-11-25 MX MXPA05005574A patent/MXPA05005574A/es active IP Right Grant
- 2003-11-25 CN CNB2003801092068A patent/CN1325466C/zh not_active Expired - Fee Related
- 2003-11-25 DK DK03783752.3T patent/DK1569892T3/da active
- 2003-11-25 AP AP2005003320A patent/AP2113A/xx active
- 2003-11-25 AU AU2003291157A patent/AU2003291157C1/en not_active Ceased
- 2003-11-25 PT PT03783752T patent/PT1569892E/pt unknown
- 2003-11-25 EP EP03783752A patent/EP1569892B1/en not_active Expired - Lifetime
- 2003-11-25 OA OA1200500152A patent/OA12962A/en unknown
-
2005
- 2005-05-19 IL IL168704A patent/IL168704A/en not_active IP Right Cessation
- 2005-05-23 MA MA28294A patent/MA27528A1/fr unknown
- 2005-05-24 CO CO05050416A patent/CO5570664A2/es active IP Right Grant
- 2005-06-02 IS IS7880A patent/IS2897B/is unknown
- 2005-06-22 NO NO20053071A patent/NO332304B1/no not_active IP Right Cessation
-
2006
- 2006-02-07 ZA ZA200504104A patent/ZA200504104B/en unknown
-
2009
- 2009-02-26 US US12/393,284 patent/US7829594B2/en not_active Expired - Fee Related
-
2010
- 2010-09-30 US US12/894,644 patent/US8399517B2/en not_active Expired - Fee Related
-
2012
- 2012-09-03 CY CY20121100784T patent/CY1113083T1/el unknown
-
2013
- 2013-02-11 US US13/764,126 patent/US8586631B2/en not_active Expired - Fee Related
- 2013-11-01 US US14/069,447 patent/US8980950B2/en not_active Expired - Fee Related
-
2015
- 2015-03-06 US US14/640,711 patent/US9227914B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2336853C (en) | Phenoxyacetic acid derivatives and medicinal compositions containing the same | |
| US9227914B2 (en) | Calcilytic compounds | |
| CN1312125C (zh) | 氨基醇衍生物及其加成盐以及免疫抑制剂 | |
| AU666162B2 (en) | Ethanolamine derivatives having sympathomimetic and anti-pollakiuria activities | |
| US20080249177A1 (en) | Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof | |
| CN100418944C (zh) | 氨基醇衍生物、含有所述氨基醇衍生物的药物组合物及其应用 | |
| HK1082914B (en) | Calcilytic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |